Clinical Trials Logo

Clinical Trial Summary

Invasive fungal infection is detecting candida species in blood, cerebrospinal fluid, or urine. Clinical signs of invasive candidiasis may include lethargy, temperature instability, feeding intolerance, apnea, hypotension, respiratory distress, abdominal distension, and thrombocytopenia. Fungal infection has been associated with an increased risk of retinopathy of prematurity and chronic lung disease. Preterm and low birth weight infants have an immature immune system that predisposes them to infections with bacteria, viruses, and fungi. These infants usually require prolonged admission in the neonatal unit and there is often a need for the administration of broad-spectrum antibiotics which predisposes them to colonization with fungi that may invade to cause systemic disease8. Other risk factors for the development of invasive fungal infection include endotracheal intubation, abdominal surgery, the presence of a central venous catheter, administration of H2 antagonists, and steroids. Infection with Candida species is the third most common cause of bloodstream infection in premature infants. Mortality in preterm infants due to invasive candidiasis is around 20% and can be as high as 50% in infants weighing <1500g at birth. Invasive candidiasis is the second most common infectious cause of death in extremely preterm infants. The present study was conducted to determine the incidence of invasive candidiasis among preterm and very low birth weight infants in our neonatal unit and to evaluate the efficacy of prophylactic fluconazole in preventing invasive fungal infection. Based on the results of the present study institutional guidelines may be designed in our neonatal unit relating to antifungal prophylaxis in preterm and very low birth weight infants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05848492
Study type Interventional
Source Services Institute of Medical Sciences, Pakistan
Contact
Status Completed
Phase Phase 3
Start date May 1, 2021
Completion date October 31, 2021

See also
  Status Clinical Trial Phase
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT03468803 - Influence of Open and Laparoscopic Abdominal Surgery Involving the Intestinal Tract on Serum 1,3-ß-D-Glucan (BDG) Values N/A
Recruiting NCT03090334 - A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis N/A
Recruiting NCT03450005 - ECMM Candida Registry - CandiReg
Completed NCT04148287 - An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris Phase 2
Recruiting NCT03717623 - Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Phase 4